This site is intended for U.S. healthcare professionals.
Coverage for TRAZIMERA varies by location. Your Pfizer Sales Representative can share plan-specific commercial and Medicare coverage rates in your region.
Approved for all indications of Herceptin, with an identical dosing and administration schedule1
Eligible,§ commercially insured patients|| may pay as little as $0 per TRAZIMERA treatment.¶ See full Terms and Conditions below.
Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar and the reference product.
WAC is a manufacturer’s undiscounted or list price to wholesalers/direct purchasers and, therefore, is not inclusive of discounts to payers, providers, distributors, and other purchasing organizations. Data as of May 2022.
NCCN Guidelines recommend the use of an FDA-approved biosimilar as an appropriate substitute for trastuzumab. See the NCCN Guidelines for detailed recommendations, including specific treatment regimens. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2023 Pfizer Inc. All rights reserved.
TRAZIMERA is indicated: